Rheumatoid Arthritis Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

July 29 00:11 2020
Rheumatoid Arthritis Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

“Rheumatoid Arthritis – Market Insights, Epidemiology, and Market Forecast-2030”

DelveInsight launched a new report on Rheumatoid Arthritis Market Insights, Epidemiology and Market Forecast-2030

 

DelveInsight’s “Rheumatoid Arthritis – Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Rheumatoid Arthritis, historical and forecasted epidemiology as well as the Rheumatoid Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the key facts of the report

  • One in 12 women and 1 in 20 men will develop an inflammatory autoimmune rheumatic disease during their lifetime.
  • About 1.5 million in the US have Rheumatoid Arthritis with a prevalence of 0.6%.
  • Japan has the lowest percentage of prevalent diagnosed and treated patients.
  • The peak age at Rheumatoid Arthritis onset shifted from the 50–59 years age group to the 60–69 years age group over the last decade

 

Key benefits of the report

1. Rheumatoid Arthritis market report covers a descriptive overview and comprehensive insight of the Rheumatoid Arthritis epidemiology and Rheumatoid Arthritis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Rheumatoid Arthritis market report provides insights on the current and emerging therapies.

3. Rheumatoid Arthritis market report provides a global historical and forecasted market covering drug outreach in 7 MM.

4. Rheumatoid Arthritis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Rheumatoid Arthritis market.

 

Request for sample pages: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market


“Women are affected by Rheumatoid Arthritis three times more than men.”

Rheumatoid Arthritis treatment landscape has progressed from the last two decade, including the diagnosis and treatment. Albeit, presently there is no cure for the disease, the goals of therapy are to decrease pain, inflammation control, preserve the ability of the patient to function in activities of daily living and work and avert joint destruction. Pharmacists and other healthcare professionals play a vital role in caring for Rheumatoid Arthritis patients. The pharmacologic approaches have relied on combinations of non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, glucocorticoids (prednisone, methylprednisone), disease-modifying anti-rheumatic drugs (DMARDs) and biologics.

Corticosteroids, including prednisone, prednisolone and methylprednisolone, are potent and quick-acting anti-inflammatory medications. They may be used to get potentially damaging inflammation under control and may be needed to control severe polyarticular disease until disease-modifying antirheumatic drugs (DMARDs) have been added and become useful.
There is now a better comprehension of the mechanisms/pathways involved in the disease, permitting site-specific drug development. There are two major types of Disease-Modifying Antirheumatic Drugs (DMARDs): biological and synthetic.

Conventional, synthetic DMARDs (csDMARDs) are not site-specific, and they do not have precise mechanisms of action for relieving the disease. Synthetic DMARDs targets to a particular site. Biological DMARDs are also site-specific (e.g., targeting TNF, IL-6, IL-1, B cells, or T cells).

 

Request for sample pages: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market

The launch of the emerging therapies is expected to significantly impact Rheumatoid Arthritis treatment scenario in the upcoming years:-

Drugs covered:

  • Filgotinib
  • Olokizumab
  • ABX464
  • And many others

 

The key players in Rheumatoid Arthritis market are:

  • Galapagos NV/Gilead Sciences
  • R-Pharm
  • Abivax
  • And many others

 

Request for sample pages: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market

 

Table of contents

1. Report Introduction

2. Rheumatoid Arthritis Market Overview at a Glance

3. Rheumatoid Arthritis Disease Background and Overview

4. Rheumatoid Arthritis Epidemiology and Patient Population

5. Rheumatoid Arthritis Country-Wise Epidemiology

6. United States

7. EU–5 Countries

7.1. Assumptions and Rationale

7.2. Germany

7.3. France

7.4. Italy

7.5. Spain

7.6. United Kingdom

7.7. Japan

8. Rheumatoid Arthritis Treatments and Medical Practices

9. Rheumatoid Arthritis Emerging Therapies

10. Key Cross Competition

10.1. Filgotinib: Galapagos NV/Gilead Sciences

10.2. Olokizumab: R-Pharm

11. Rheumatoid Arthritis Market Size

12. 7MM Rheumatoid Arthritis Country-Wise Market Analysis

13. United States Market Size

14. EU5 Market Size

14.1. Germany Market Size

14.2. France Market Size

14.3. Italy Market Size

14.4. Spain Market Size

14.5. UK Market Size

15. Japan Market Size

16. Rheumatoid Arthritis Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

 

Request For Detailed TOC: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/goaheadlines.org/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7